Bayer AG has identified α2C-adrenoceptor antagonists reported to be useful for the treatment of dysphagia, snoring, neurodegeneration, neuroinflammation and cardiovascular disorders.

Bristol Myers Squibb Co. has synthesized receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of inflammatory bowel disease, psoriasis, rheumatoid arthritis, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), multiple sclerosis, amyotrophic lateral sclerosis, heart failure and Alzheimer’s disease.

Chengdu Chipscreen Pharmaceutical Ltd. has disclosed integrin αvβ1 and/or αvβ6 antagonists reported to be useful for the treatment of fibrosis.

Neushen Therapeutics Inc. has described NLRP3 inflammasome inhibitors reported to be useful for the treatment of autoimmune disease, cardiovascular disorders, neurodegeneration and chronic obstructive pulmonary disease.

Negio Therapeutics NV has divulged guanfacine derivatives acting as α2-adrenoceptor agonists reported to be useful for the treatment of cancer.

Nuvalent Inc. has identified proto-oncogene tyrosine-protein kinase ROS (ROS1; MCF3) and/or ALK tyrosine kinase receptor inhibitors reported to be useful for the treatment of cancer.

Researchers at Bexson Biomedical Inc. and Saint Joseph’s University have synthesized NMDA receptor antagonists reported to be useful for the treatment of neurological and psychiatric disorders.

Crinetics Pharmaceuticals Inc. has disclosed somatostatin receptor type 3 (SSTR3) agonists reported to be useful for the treatment of autosomal dominant polycystic kidney disease.

Korea University Research & Business Foundation Sejong Campus has described thiobenzimidazole derivatives reported to be useful for the treatment of breast cancer.

The University of Michigan has divulged lysine-specific histone demethylase 1A (KDM1A; LSD1) inhibitors reported to be useful for the treatment of cancer, autism, myocardial fibrosis and more.